Jenna Foger, VP, science and technology, Alexandria Venture Investments, is one of the 100 leading corporate venturing professionals in our 2025 Powerlist.

Jenna Foger is senior vice president, science and technology at Alexandria Venture Investments, the investment arm of Alexandria Real Estate Equities, a US real estate investment trust that holds many scientific organisations and businesses as tenants.
Her role involves supporting the venture investments by providing industry insights and scientific expertise. She brings a scientific background to the job, holding a Bachelor of Arts degree in cognitive neuroscience from the University of Pennsylvania, where she graduated summa cum laude. After that, she received a master’s degree in biotechnology from Columbia University.
Foger has been at Alexandria for more than a decade, having joined in 2014. She led the strategic planning for Alexandria LaunchLabs, a startup accelerator for early-stage life sciences and agtech companies. Since its inception in 2018, she has been heavily involved in the Alexandria Seed Capital Platform, which aims to accelerate seed funding in the life sciences sector.
She brings a scientific background to the job, holding a BA in cognitive neuroscience and a master’s degree in biotechnology from Columbia University.
On the real estate side of Alexandria’s business, Foger underwrites the tenants and acts as a point of contact for them, which involves understanding their science R&D programmes and business health.
Alexandria Venture Investments primarily invests in biotech and healthcare startups, with a focus on pharmaceuticals. It is one of the most prolific investors in GCV’s CVC Funding Round Database.
In February, Alexandria Venture Investments took part in the $350m series D funding round for Eikon Therapeutics, a US biotech company that uses advanced biological engineering and molecular and cell biology in drug discovery. Its lead product is a drug to treat melanoma, which the company calls EIK1001, which is now in a phase-three trial.
Alexandria was not Foger’s first experience in healthcare venturing. Before she joined, she was an associate at Windham Venture Partners, a US VC firm, for just over a year. There, she expanded the healthcare venture fund, focusing on medical technology, diagnostics and digital health investments.

The Global Corporate Venturing Powerlist represents the 100 individuals spearheading the future of the corporate venturing industry.
These individuals excel in terms of their venturing approach and structure, number and quality of portfolio companies and in their contributions to the corporate venturing profession.